18775-42-3

Upstream product

• 50-00-0 formaldehyd 
• 496-11-7 INDANE 
• 501649-52-1 5-(bromomethyl)-2,3-dihydro-1H-indene 
• 30084-91-4 indan-5-carbaldehyde 
• 86031-43-8 methyl 5-indanecarboxylate 
• 113364-54-8 1-(2-indan-5-yl-2-oxo-ethyl)-pyridinium; iodide 
• 86119-84-8 phosphoric acid 
• 65898-38-6 indan-5-carboxylic acid 
• 4228-10-8 1-indan-5-yl-ethanone 
• 6134-54-9 5-bromoindane 
• 24425-40-9 indan-5-amine 
• 112504-90-2 5-Indanylmethylmethylether 
• 5266-64-8 1,4,5,6-tetrahydrocyclopropindene 
• 51632-06-5 (2,3-dihydro-1H-inden-5-yl)methanol 

Downstream Products

• 18775-43-4 (5-indanyl)acetonitrile 
• 54889-55-3 5-hexyl-2,3-dihydro-1H-indene 
• 30084-91-4 indan-5-carbaldehyde 
• 1187212-05-0 4-(indan-5-ylmethoxy)benzaldehyde 
• 125868-59-9 2-(o-Carboxybenzyl)-3-(5-indanyl)-propansaeure 
• 125868-72-6 2-Benzyl-as-hydrindacen-1-on-4-carbonsaeure 
• 13203-56-0 indan-5-ylmethylamine 

Relevant academic research and scientific papers

Aromatic Spiranes, XV. Syntheses of 2,2'-Spirobi-(s-hydrindacene)-1,1'-dione and of 4,4'-Disubstituted 2,2'-Spirobi-(s-hydrindacenes)

The title compound 6a was prepared by cyclisation of the diacid 4b.The diester 4a of 4b was synthesized by alkylation of 2 with 3 and following Retro-Claisen-reaction.After catalytic reduction of 6a to 8a two identical substituents were introduced by Friedel-Crafts-reaction (28).By transformation of the acetylgroups several other derivatives (29-36) could be obtained.The unsymmetrical compounds (e.g. 21) were prepared from 20, whose precurser was the spiroketon 10a. - Keywords: s-Hydrindacen-1-one and derivatives; Cyclisation; 2,2'-Spirobiindane-1,1'-diones; 2,2'-Spirobiindane-1-ones; 2,2'-Spirobiindanes; 1H nmr spectra; Mass spectra

Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype

As universal heterodimer partners of many nuclear receptors, the retinoid X receptors (RXRs) constitute key transcription factors. They regulate cell proliferation, differentiation, inflammation, and metabolic homeostasis and have recently been proposed as potential drug targets for neurodegenerative and inflammatory diseases. Owing to the hydrophobic nature of RXR ligand binding sites, available synthetic RXR ligands are lipophilic, and their structural diversity is limited. Here, we disclose the computer-assisted discovery of a novel RXR agonist chemotype and its systematic optimization toward potent RXR modulators. We have developed a nanomolar RXR agonist with high selectivity among nuclear receptors and superior physicochemical properties compared to classical rexinoids that appears suitable for in vivo applications and as lead for future RXR-targeting medicinal chemistry.

NOVEL PROTEIN TYROSINE PHOSPHATASE - IB INHIBITORS

The present invention relates to the novel compounds of the general formula (I), wherein the symbols are same as described in specification, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, to process and intermediates for the preparation of the above said compounds, having the utility of these compounds in medicine and to methods for their therapeutic use, and their use in the treatment of metabolic disorders.

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

Two classes of p38α MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes

Two new classes of diphenylether inhibitors of p38α MAP kinase are described. Both chemical classes are based on a common diphenylether core that is identified by simulated fragment annealing as one of the most favored chemotypes within a prominent hydrophobic pocket of the p38α ATP-binding site. In the fully elaborated molecules, the diphenylether moiety acts as an anchor occupying the deep pocket, while polar extensions make specific interactions with either the adenine binding site or the phosphate binding site of ATP. The synthesis, crystallographic analysis, and biological activity of these p38α inhibitors are discussed.

SYNTHESIS OF TRICYCLIC BENZAZEPINES AND THEIR DOPAMINE D1- AND D2-AFFINITY

A new group of angular 8,9-annelated 3-benzazepines has been found to be potent and selective dopamine D1-receptor antagonists of interest as possible pharmaceuticals in the treatment of schizophrenia.The synthesis of three new conformationally constrained representatives of this group of benzazepines is described and their affinity to the D1-receptor evaluated.Although none of these proved superior to the previously examined compounds, useful information on the receptor binding site was obtained.

Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides

A series of substituted 3H-1,2,3,5-oxathiadiazole-2-oxides (6) was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. The oxathiadiazoles 6 were synthesized by a two-step sequence: treatment of a substituted acetonitrile (4) with hydroxylamine to give the corresponding amidoxime (5) and cyclization with thionyl chloride to yield 6. In terms of potency, the 2-naphthalenylmethyl group (as in compound 3) was found to be the optimal substituent in this series. Compound 3 was approximately 5 times more potent than ciglitazone (1).

Novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides useful as anthihyperglycemic agents

This invention relates to novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides, to the processes for their preparation, to methods for using the compounds, and to pharmaceutical compositions thereof. The compounds have pharmaceutical properties which render them beneficial for the treatment of diabetes mellitus and associated conditions.

Aromatic Spiranes, XIV: Syntheses of 2,2'-Spirobi-(s-hydrindacene) and its precursors

The title compound 35 was prepared by catalytic reduction of the diones 29a and 11a. 29a was synthesized by systematic anellation of fivemembered rings to the positions 5,6 and 5',6', resp., of 2,2'-spirobiindane.The preparation of 11a was achieved by Friedel-Crafts cyclisation of bis-(5-indanylmethyl)-malonic acid. s-Hydrindacene-1-one 5a was prepared as a precursor for the synthesis of 11a (see forthcoming publication) and its derivates as models for corresponding anellation and substitution reactions. - Keywords: s-Hydrindacene-1-one and derivates; Mono- and bisanellation; 2,2'-Spirobiindane; 1H-nmr spectra